Investigating the role of costimulatory domains in enhancing CAR-T cell persistence in TNBC
- 1Department of Cytology and Histology, Faculty of Veterinary Medicine, Mansoura University, Mansoura, Egypt
- 2Section of Pharmacology, Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore-Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
- 3Institute of Translational Pharmacology-CNR, Rome, Italy
Abstract
This work summarizes how costimulatory domains can mediate the persistence, function, and therapeutic potential of CAR-T cells in triple-negative breast cancer (TNBC), a highly aggressive malignancy with limited treatment options and an immunosuppressive tumor microenvironment. Although CAR-T cell therapy has produced remarkable results in hematologic malignancies, its translation to TNBC remains limited by poor T cell persistence, metabolic dysfunction, and rapid exhaustion. Current evidence identifies canonical costimulatory domains (CD28 and 4-1BB) as having differential effects on intracellular signaling, metabolic programming, and T cell differentiation; CD28-based CAR-T cells promote rapid activation and glycolytic metabolism but are commonly associated with terminal differentiation and decreased durability, whereas 4-1BB signaling supports mitochondrial fitness, oxidative phosphorylation, and the development of memory-like T cells that support longer-lasting persistence. The functional differences in CAR-T cells are context-dependent and influenced by antigen density, hypoxia, and other immunosuppressive signals within the TNBC tumor microenvironment. Newer costimulatory domains, such as HVEM and TNFRSF9, have added an additional layer of complexity to T cell signaling by modulating activating and inhibitory pathways, and their incorporation into CAR designs offers new ways to optimally regulate T cell responses; however, their functions are not fully defined in TNBC models. Additionally, dual costimulation strategies and combination therapies (metabolic reprogramming of T cells, epigenetic modulation, and immune checkpoint blockade) have shown promise in preclinical studies, but their translational value remains to be validated. An important message arising from this review is that while persistence may be improved through enhanced costimulatory signaling, the ideal performance of CAR T therapy occurs with the establishment of an ideal balance of stimulating signals that promote the sustained function of effector T cells while inhibiting the exhaustion of T cells and avoiding the deleterious effects of tonic activation. Furthermore, it is critical to evaluate data from TNBC models compared to other solid tumors to inform rational CAR T design strategies in TNBC.
Related
- 170 Enhancing γδ CAR T cell function through alternative CD3 cytoplasmic domains
- ENGINEERING MANNAN-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (M-CAR) T CELLS WITH DISTINCT COSTIMULATORY DOMAINS TO IMPROVE ANTIFUNGAL ACTIVITY AGAINST
- 1175 Combining PSMAxCD28 costimulatory T cell engager (TCE) JNJ-87189401 with pasritamig (KLK2xCD3): first-in-human phase 1 results of a dual-antigen targeted TCE regimen in prostate cancer
- Investigating the effect of theory-based educational intervention on enhancing physical activity and reducing weight among overweight and obese students
- 931 A TCF7 phosphorylation checkpoint controls B7-H3 CAR-T cell persistence in solid tumors and brain metastases
BibTeX
@article{marei2026investigating,
title = {{Investigating the role of costimulatory domains in enhancing CAR-T cell persistence in TNBC}},
author = {Hany E. Marei and Giacomo Pozzoli and Carlo Cenciarelli},
journal = {Cancer Gene Therapy},
year = {2026},
month = aug,
doi = {10.1038/s41417-026-01073-0},
url = {https://doi.org/10.1038/s41417-026-01073-0},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Investigating the role of costimulatory domains in enhancing CAR-T cell persistence in TNBC
AU - Hany E. Marei
AU - Giacomo Pozzoli
AU - Carlo Cenciarelli
PY - 2026
DA - 2026/08/21
JO - Cancer Gene Therapy
DO - 10.1038/s41417-026-01073-0
UR - https://doi.org/10.1038/s41417-026-01073-0
AB - This work summarizes how costimulatory domains can mediate the persistence, function, and therapeutic potential of CAR-T cells in triple-negative breast cancer (TNBC), a highly aggressive malignancy with limited treatment options and an immunosuppressive tumor microenvironment. Although CAR-T cell therapy has produced remarkable results in hematologic malignancies, its translation to TNBC remains limited by poor T cell persistence, metabolic dysfunction, and rapid exhaustion. Current evidence identifies canonical costimulatory domains (CD28 and 4-1BB) as having differential effects on intracellular signaling, metabolic programming, and T cell differentiation; CD28-based CAR-T cells promote rapid activation and glycolytic metabolism but are commonly associated with terminal differentiation and decreased durability, whereas 4-1BB signaling supports mitochondrial fitness, oxidative phosphorylation, and the development of memory-like T cells that support longer-lasting persistence. The functional differences in CAR-T cells are context-dependent and influenced by antigen density, hypoxia, and other immunosuppressive signals within the TNBC tumor microenvironment. Newer costimulatory domains, such as HVEM and TNFRSF9, have added an additional layer of complexity to T cell signaling by modulating activating and inhibitory pathways, and their incorporation into CAR designs offers new ways to optimally regulate T cell responses; however, their functions are not fully defined in TNBC models. Additionally, dual costimulation strategies and combination therapies (metabolic reprogramming of T cells, epigenetic modulation, and immune checkpoint blockade) have shown promise in preclinical studies, but their translational value remains to be validated. An important message arising from this review is that while persistence may be improved through enhanced costimulatory signaling, the ideal performance of CAR T therapy occurs with the establishment of an ideal balance of stimulating signals that promote the sustained function of effector T cells while inhibiting the exhaustion of T cells and avoiding the deleterious effects of tonic activation. Furthermore, it is critical to evaluate data from TNBC models compared to other solid tumors to inform rational CAR T design strategies in TNBC.
SN - 0929-1903
SN - 1476-5500
ER -